{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010116","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.866766+00:00","generated_at":"2026-05-16T10:59:55.937426+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M","bullets":["Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.","ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.","PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.","CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.","Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010116","json":"https://secwatch.observer/filing/0001193125-26-010116.json","markdown":"https://secwatch.observer/filing/0001193125-26-010116.md","text":"https://secwatch.observer/filing/0001193125-26-010116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/0001193125-26-010116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/srpt-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:55.937426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}